199 related articles for article (PubMed ID: 25401269)
21. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.
Zagouri F; Kastritis E; Gavriatopoulou M; Sergentanis TN; Psaltopoulou T; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2014 Sep; 55(9):2018-23. PubMed ID: 24295131
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
Oyama T; Taoka K; Chiba A; Masamoto Y; Ikemura M; Honda A; Maki H; Kurokawa M
Int J Hematol; 2023 Mar; 117(3):463-467. PubMed ID: 36202948
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
24. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
San-Miguel JF; Dimopoulos MA; Stadtmauer EA; Rajkumar SV; Siegel D; Bravo ML; Olesnyckyj M; Knight RD; Zeldis JB; Harousseau JL; Weber DM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):38-43. PubMed ID: 21273172
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
27. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
28. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.
He T; Zhao A; Zhao H; Cai H; Feng J; Zhang L; Cao X; Zhou D; Li J
Ann Hematol; 2019 Mar; 98(3):735-743. PubMed ID: 30612232
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
32. Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone.
Gao Y; Zhang S; Yang L; Li J; Liu Y; Wang T
Front Immunol; 2021; 12():681360. PubMed ID: 34025681
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Kim K; Kim SJ; Voelter V; Suh C; Yoon SS; Lee JJ; Kwak JY; Ryoo HM; Kim YS; Moon JH; Park SK; Kim SH; Mun YC; Kim JS; Eom HS; Jo DY; Jun HJ; Kim KH; Lee JO; Lee JH; Min CK;
Ann Hematol; 2014 Jan; 93(1):113-21. PubMed ID: 24026427
[TBL] [Abstract][Full Text] [Related]
34. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C; Singhal AK; Jagannath S
J Clin Oncol; 2012 Jun; 30(16):1953-9. PubMed ID: 22547589
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S; Sato Y; Katayama K; Nagashima K; Aoyagi R; Sekiguchi Y; Sobue G; Koike H; Yabe I; Sasaki H; Watanabe O; Takashima H; Nishizawa M; Kawachi I; Kusunoki S; Mitsui Y; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
Lancet Neurol; 2016 Oct; 15(11):1129-37. PubMed ID: 27496680
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Zago M; Oehrlein K; Rendl C; Hahn-Ast C; Kanz L; Weisel K
Ann Hematol; 2014 Dec; 93(12):1993-9. PubMed ID: 24974802
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
[TBL] [Abstract][Full Text] [Related]
38. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
39. [Autologous peripheral blood stem cell transplantation for POEMS syndrome].
Liao LS; Zheng ZH; Qu S; Wei TN; Xie Y; Lin Y; Chen BY; Chen WM
Zhonghua Nei Ke Za Zhi; 2019 Mar; 58(3):209-212. PubMed ID: 30803180
[TBL] [Abstract][Full Text] [Related]
40. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
